Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Health problems news

Show

From To
First look at big 75-and-older HIV group - diagnosed at age 62

Compared with HIV patients between 50 and 75 years old, those 75 and older had a similar rate of viral suppression but significantly more age-linked noncommunicable comorbidities. This 15-site French study found that 98% of the 75-and-older group were taking antiretroviral therapy.

Published
07 March 2016
From
NATAP
Modest kidney function decline in people taking Truvada for PrEP supports need for monitoring

Participants taking tenofovir/emtricitabine (Truvada) for pre-exposure prophylaxis (PrEP) in two major studies experienced modest declines in kidney function that were associated with higher tenofovir drug levels and older

Published
02 March 2016
By
Liz Highleyman
Study does not support routine HPV quadrivalent vaccination to protect against anal cancer in older people living with HIV

The quadrivalent HPV vaccine Gardasil does not protect older adults with HIV against persistent anal infection with human papillomavirus (HPV) or the development of HSIL, but the

Published
29 February 2016
By
Keith Alcorn
Cardiovascular Risk Tools for HIV Go Head-to-Head in Large U.S. Study

A cardiovascular risk-scoring system known as ASCVD appears to be a better predictor of myocardial infarction (MI) among people with HIV than other risk scores, including Framingham and D:A:D, according to new research.

Published
26 February 2016
From
The Body Pro
Antidepressant May Improve Cognitive Symptoms in People with HIV

In a small, placebo-controlled clinical trial, Johns Hopkins physicians report that the antidepressant paroxetine modestly improves decision-making and reaction time, and suppresses inflammation in people with HIV-associated cognitive impairment.

Published
26 February 2016
From
Hopkins Medicine
Early antiretroviral therapy reduces the risk of infection-related cancers

People who started antiretroviral therapy at a CD4 cell count above 500 had a significantly lower risk of developing a cancer with an infectious cause when compared

Published
25 February 2016
By
Keith Alcorn
HIV in the brain: new tools and treatment to keep your mind beautiful

In the future, HIV-associated neurocognitive disorder (HAND) may become less common because of the earlier use of antiretroviral therapy (ART), but neurological disease – caused by a

Published
25 February 2016
By
Theo Smart
TAF/emtricitabine maintains viral suppression as well as TDF regimens with less bone and kidney toxicity

A fixed-dose coformulation of tenofovir alafenamide (TAF) and emtricitabine (FTC, Emtriva), combined with a variety of third antiretroviral agents, maintained undetectable viral load in people who switched

Published
25 February 2016
By
Liz Highleyman
Bone density recovers quickly after stopping PrEP

Bone mineral density recovers within six months of stopping pre-exposure prophylaxis (PrEP) containing tenofovir, Bob Grant of the University of California, San Francisco reported on behalf of

Published
24 February 2016
By
Keith Alcorn
Early antiretroviral therapy has no impact on marker of early cardiovascular disease

Starting treatment at a CD4 cell count above 500 does not lead to improvement in an important early warning sign of cardiovascular disease, and investigators are still

Published
23 February 2016
By
Keith Alcorn

Filter by country